WHO ICTRP trial
AVAstin and Temozolomide Attacking Relapsed glioma
ISRCTN23008679 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN23008679 |
|---|---|
| Public title | AVAstin and Temozolomide Attacking Relapsed glioma |
| Scientific title | Bevacizumab in combination with metronomic dose temozolomide in patients with relapsed high grade gliomas |
| Primary sponsor | Academic Medical Centre (AMC) (The Netherlands) |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not Specified |
| Countries | Netherlands |
| Conditions | Relapsed glioma Cancer Neoplasms |
| Interventions | The effects of the combination of Bevacizumab (10 mg every three weeks, intravenously [iv]) with daily Temozolomide (50 mg/m^2, orally) will be compared with historical data of a matched patient group. The MRI effects of (co-)… |
| Registration date | Jul 16, 2007 |
| Target size | 30 |
| Secondary IDs | 15598 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: